Abstract:Background: Vascular smooth muscle cells (VSMCs) show a remarkable phenotypic plasticity, allowing acquisition of contractile or synthetic states, but critical information is missing about the physiologic signals, promoting formation, and maintenance of contractile VSMCs in vivo. BMP9 and BMP10 (bone morphogenetic protein) are known to regulate endothelial quiescence after secretion from the liver and right atrium, whereas a direct role in the regulation of VSMCs was not investigated. We studied the role of BMP9 and BMP10 for controlling formation of contractile VSMCs. Methods: We generated several cell type-specific loss- and gain-of-function transgenic mouse models to investigate the physiologic role of BMP9, BMP10, ALK1 (activin receptor-like kinase 1), and SMAD7 in vivo. Morphometric assessments, expression analysis, blood pressure measurements, and single molecule fluorescence in situ hybridization were performed together with analysis of isolated pulmonary VSMCs to unravel phenotypic and transcriptomic changes in response to absence or presence of BMP9 and BMP10. Results: Concomitant genetic inactivation of Bmp9 in the germ line and Bmp10 in the right atrium led to dramatic changes in vascular tone and diminution of the VSMC layer with attenuated contractility and decreased systemic as well as right ventricular systolic pressure. On the contrary, overexpression of Bmp10 in endothelial cells of adult mice dramatically enhanced formation of contractile VSMCs and increased systemic blood pressure as well as right ventricular systolic pressure. Likewise, BMP9/10 treatment induced an ALK1-dependent phenotypic switch from synthetic to contractile in pulmonary VSMCs. Smooth muscle cell-specific overexpression of Smad7 completely suppressed differentiation and proliferation of VSMCs and reiterated defects observed in adult Bmp9/10 double mutants. Deletion of Alk1 in VSMCs recapitulated the Bmp9/10 phenotype in pulmonary but not in aortic and coronary arteries. Bulk expression analysis and single molecule RNA-fluorescence in situ hybridization uncovered vessel bed-specific, heterogeneous expression of BMP type 1 receptors, explaining phenotypic differences in different Alk1 mutant vessel beds. Conclusions: Our study demonstrates that BMP9 and BMP10 act directly on VSMCs for induction and maintenance of their contractile state. The effects of BMP9/10 in VSMCs are mediated by different combinations of BMP type 1 receptors in a vessel bed-specific manner, offering new opportunities to manipulate blood pressure in the pulmonary circulation.

BMP10 preserves cardiac function through its dual activation of SMAD-mediated and STAT3-mediated pathways

Bone Morphogenetic Protein-10 Induces Cardiomyocyte Proliferation and Improves Cardiac Function after Myocardial Infarction

Bone Morphogenetic Protein 10 Alleviates Doxorubicin-Induced Cardiac Injury Via Signal Transducer and Activator of Transcription 3 Signaling Pathway

Bone morphogenetic protein 10, a rising star in the field of diabetes and cardiovascular disease

Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics

BMP6 knockdown enhances cardiac fibrosis in a mouse myocardial infarction model by upregulating AP-1/CEMIP expression

Abstract 18640: Recombinant Bone Morphogenetic Protein 9 is a Novel Therapeutic That Rescues Cardiac Fibrosis and Improves Cardiac Function in Heart Failure

bmp10 maintains cardiac function by regulating iron homeostasis

Exogenous BMP-7 Facilitates the Recovery of Cardiac Function after Acute Myocardial Infarction Through Counteracting TGF-β1 Signaling Pathway

Bone Morphogenetic Protein 6 Alleviates Cardiac Fibrosis and Dysfunction in Heart Failure

Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex.

MicroRNA-19a-3p augments TGF-β1-induced cardiac fibroblast activation via targeting BAMBI

Bmp7 Counteracts Tgf Beta1 Induced Endothelial-To-Mesenchymal Transition in Viral Cardiomyopathy and Its Potential Mechanism

BMP9 and BMP10 Act Directly on Vascular Smooth Muscle Cells for Generation and Maintenance of the Contractile State.

Myoblast Transplantation Improves Cardiac Function after Myocardial Infarction Through Attenuating Inflammatory Responses.

BMP7-based peptide agonists of BMPR1A protect the left ventricle against pathological remodeling induced by pressure overload

Bone morphogenetic protein-2 acts upstream of myocyte-specific enhancer factor 2a to control embryonic cardiac contractility.

BMP10 Knockdown Modulates Endothelial Cell Immunoreactivity by Inhibiting the HIF‐1α Pathway in the Sepsis‐Induced Myocardial Injury

Astragalus polysaccharides alleviates cardiac hypertrophy in diabetic cardiomyopathy via inhibiting the BMP10-mediated signaling pathway

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

BMP7 promotes cardiomyocyte regeneration in zebrafish and adult mice